CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer

Frontiers in Oncology

Jiu-Min Liu¹  Wei-Peng Liu²  Hui-Jun Qian³  Xian-Lin Yi⁴  Xin Gao⁵  Yu-Sheng Xu⁶  Jue Wang⁷  Yu-Hang Pan⁸  Jing Zhou⁸  Xin Chen⁹  Cheng-Huizi Yang^1,10  Qi-Ji Lu^1,11  Yong-Hong Li^1,12  Yu-Min Zhuo^1,13  Zheng Chen^1,13  Jian-Fan Chen^1,13  Cai-Yong Lai^1,13  Xiao-Ping Qin^1,13  Li-Jun Qu^1,13  Shan-Cheng Ren^1,14  Kan Liu^1,15 

[1] 0Department of Urology, Guangdong General Hospital, Guangzhou, China;1Department of Urology, The First Affiliated Hospital, Nanchang University, Nanchang, China;2Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China;3Department of Urology, Cancer Hospital, Guangxi Medical University, Nanning, China;4Department of Urology, The Third Affiliated Hospital of Sun Yet-Sen University, Guangzhou, China;5Department of Emergency, The First Affiliated Hospital of Jinan University, Guangzhou, China;Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pathology, The Third Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China;Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China;Department of Urology, Affiliated Xiaolan Hospital, Southern Medical University, Zhongshan, China;Department of Urology, Cancer Center, Sun Yat-sen University, Guangzhou, China;Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou, China;Department of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai, China;Department of Urology, The Third Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China;

关键词: prostate cancer;    gleason score upgrade;    CRMP4 promoter methylation;    biochemical recurrence;    pelvic lymph node dissection;   

DOI  :  10.3389/fonc.2022.840950

来源: DOAJ

【 摘 要 】

BackgroundThis study determined the predictive value of CRMP4 promoter methylation in prostate tissues collected by core needle biopsies for a postoperative upgrade of Gleason Score (GS) to ≥8 in patients with low-risk PCa.MethodA retrospective analysis of the clinical data was conducted from 631 patients diagnosed with low-risk PCa by core needle biopsy at multiple centers and then underwent Radical Prostatectomy (RP) from 2014-2019. Specimens were collected by core needle biopsy to detect CRMP4 promoter methylation. The pathologic factors correlated with the postoperative GS upgrade to ≥8 were analyzed by logistic regression. The cut-off value for CRMP4 promoter methylation in the prostate tissues collected by core needle biopsy was estimated from the ROC curve in patients with a postoperative GS upgrade to ≥8.ResultMultivariate logistic regression showed that prostate volume, number of positive cores, and CRMP4 promoter methylation were predictive factors for a GS upgrade to ≥8 (OR: 0.94, 95% CI: 0.91-0.98, P=0.003; OR: 3.16, 95% CI: 1.81-5.53, P<0.001; and OR: 1.43, 95% CI: 1.32-1.55, P<0.001, respectively). The positive predictive rate was 85.2%, the negative predictive rate was 99.3%, and the overall predictive rate was 97.9%. When the CRMP4 promoter methylation rate was >18.00%, the low-risk PCa patients were more likely to escalate to high-risk patients. The predictive sensitivity and specificity were 86.9% and 98.8%, respectively. The area under the ROC curve (AUC) was 0.929 (95% CI: 0.883-0.976; P<0.001). The biochemical recurrence (BCR)-free survival, progression-free survival (PFS), and cancer-specific survival (CSS) were worse in patients with CRMP4 methylation >18.0% and postoperative GS upgrade to ≥8 than in patients without an upgrade (P ≤ 0.002).ConclusionA CRMP4 promoter methylation rate >18.00% in prostate cancer tissues indicated that patients were more likely to escalate from low-to-high risk after undergoing an RP. We recommend determining CRMP4 promoter methylation before RP for low-risk PCa patients.

【 授权许可】

Unknown